Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review

References

• Ramsawh HJ, Chavira DA, Stein MB. Burden of anxiety disorders in pediatric medical settings: prevalence, phenomenology, and a research agenda. Arch. Pediatr. Adolesc. Med. 2010;164(10):965–972.
   Google Scholar
• Baxter AJ, Vos T, Scott KM, et al. The global burden of anxiety disorders in 2010. Psychol. Med. 2014;44:2363–2374.
   PubMed Web of Science ®Google Scholar
• Beesdo-Baum K, Knappe S. Developmental epidemiology of anxiety disorders. Child Adolesc. Psychiatr. Clin. N. Am. 2012;21:457–478.
   PubMed Web of Science ®Google Scholar
• Beesdo K, Pine DS, Lieb R, et al. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch. Gen. Psychiatry. 2010;67:47–57.
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Wittchen HU, Ballenger JC, et al. Generalized anxiety disorder: nature and course. J. Clin. Psychiatry. 2001;62(Suppl 11):15–21.
   Google Scholar
• Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress. Anxiety. 2002;16:162–171.
   PubMed Web of Science ®Google Scholar
• Hoffman DL, Dukes EM, Wittchen H-U. Human and economic burden of generalized anxiety disorder. Depress. Anxiety. 2008;25:72–90.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Kessler RC, Pfister H, et al. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr. Scand. Suppl. 2000;14–23.
   PubMedGoogle Scholar
• Pine D, Cohen P, Gurley D, et al. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch. Gen. Psychiatry. 1998;55:56–64.
   PubMed Web of Science ®Google Scholar
• Husky MM, Olfson M, He J, et al. Twelve-month suicidal symptoms and use of services among adolescents: results from the national comorbidity survey. Psychiatr. Serv. [Internet]. 2012;63:989–996.
   PubMed Web of Science ®Google Scholar
• Nepon J, Belik SL, Bolton J, et al. The relationship between anxiety disorders and suicide attempts: findings from the national epidemiologic survey on alcohol and related conditions. Depress. Anxiety. 2010;27:791–798.
   PubMed Web of Science ®Google Scholar
• Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N. Engl. J. Med. 2008;359:2753–2766.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Sakolsky DJ, Rynn MA. Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adolesc.Psychiatr.Clin. N Am. 2012;21:527–539.
   PubMed Web of Science ®Google Scholar
• Beidel DC, Turner SM, Sallee FR, et al. SET-C versus fluoxetine in the treatment of childhood social phobia. J. Am. Acad. Child Adolesc. Psychiatry. 2007;46:1622–1632.
   PubMed Web of Science ®Google Scholar
• Wetherell JL, Petkus AJ, White KS, et al. Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. Am. J. Psychiatry. 2013;170:782–789.
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 2007;21:864–872.
   PubMed Web of Science ®Google Scholar
• Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14:S1.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British association for psychopharmacology. J. Psychopharmacol. 2014;28:403–439.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 1994;26:201–214.
   PubMed Web of Science ®Google Scholar
• Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs. 1992;43:3–10.
   PubMedGoogle Scholar
• Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry. 2003;42:415–423.
   PubMed Web of Science ®Google Scholar
• Warrington SJ. Clinical implications of the pharmacology of sertraline. Int. Clin. Psychopharmacol. 1991;6(Suppl 2):11–21.
   PubMedGoogle Scholar
• Rudberg I, Hermann M, Refsum H, et al. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur. J. Clin. Pharmacol. 2008;64:1181–1188.
   PubMed Web of Science ®Google Scholar
• Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin. Pharmacol. Ther. 2001;70:42–47.
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J. Child Adolesc. Psychopharmacol. 2006;16:131–145.
   PubMed Web of Science ®Google Scholar
• Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am. J. Psychiatry. 2001;158:2008–2014.
   PubMed Web of Science ®Google Scholar
• Rynn MA, Walkup JT, Compton SN, et al. Child/adolescent anxiety multimodal study: evaluating safety. J. Am. Acad. Child Adolesc. Psychiatry. 2015;54:180–190.
   PubMed Web of Science ®Google Scholar
• Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry. 2001;62:350–357.
   PubMed Web of Science ®Google Scholar
• Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry. 2003;160:749–756.
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang -C-C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry. 2005;17:65–69.
   PubMedGoogle Scholar
• Roseboom PH, Kalin NH. Citalopram and S-citalopram. 4th ed. ed. Am. Psychiatric Publishing. Textbook of Psychopharmacol; 2013.
   Google Scholar
• Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J. Clin. Psychiatry. 2014;75(5):e441-9.
   Web of Science ®Google Scholar
• Baumann P. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). Int. Clin. Psychopharmacol. 1992;6(Suppl 5):13–20.
   PubMedGoogle Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J. Affect. Disord. 2005;87:161–167.
   PubMed Web of Science ®Google Scholar
• Allgulander C, Florea I, Akt H. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. 2006;9:495–505.
   PubMed Web of Science ®Google Scholar
• Sheehan DV. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. J. Clin. Psychiatry. 2001;62:26–31.
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry. 2000;157:968–974.
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. JAMA [Internet]. 2000;283:3082.
   Google Scholar
• Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months’ treatment of generalized anxiety disorder with venlafaxine extended release. Arch. Gen. Psychiatry. 2010;67:1274–1281.
   PubMed Web of Science ®Google Scholar
• Rynn MA, Riddle MA, Yeung PP, et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am. J. Psychiatry. 2007;164:290–300.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang G, Yang S, et al. Duloxetine in treating generalized anxiety disorder in adults: a meta-analysis of published randomized, double-blind, placebo-controlled trials. Asia. Pac. Psychiatry. 2016;8:215–225.
   Google Scholar
• Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18:673–681.
   PubMed Web of Science ®Google Scholar
• Alaka KJ, Noble W, Montejo A, et al. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int. J. Geriatr. Psychiatry. 2014;29:978–986.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Prakash A, Zhang Q, et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015;54:283–293.
   PubMed Web of Science ®Google Scholar
• RUPP. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J. Am. Acad. Child Adolesc. Psychiatry. 2002;41:1061–1069.
   PubMed Web of Science ®Google Scholar
• Gommoll C, Durgam S, Mathews M, et al. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress. Anxiety. 2015;32:451–459.
   PubMed Web of Science ®Google Scholar
• Durgam S, Gommoll C, Forero G, et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial. J. Clin. Psychiatry. 2016;77:1687–1694.
   PubMed Web of Science ®Google Scholar
• Sato H, Ito C, Tashiro M, et al. Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: A positron emission tomography study in healthy volunteers. Psychopharmacology (Berl). 2013;230:227–234.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Puig A, DeVane CL, et al. Mirtazapine in major depression with comorbid generalized anxiety disorder. J. Clin. Psychiatry. 1999;60:446–448.
   PubMed Web of Science ®Google Scholar
• Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J. Psychopharmacol. 2005;19:483–487.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev. Neurother. 2016;16(5):483–495.
   Web of Science ®Google Scholar
• Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur. Neuropsychopharmacol. 2012;22:847–857.
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur. Neuropsychopharmacol. 2012;22:858–866.
   PubMed Web of Science ®Google Scholar
• Christensen MC, Loft H, Florea I, et al. Efficacy of vortioxetine in working patients with generalized anxiety disorder. CNS Spectr. 2017;1–9.
   Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int. J. Clin. Pract. 2014;68:49–59.
   PubMed Web of Science ®Google Scholar
• Pae C-U, Wang S-M, Han C, et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J. Psychiatr. Res. 2015;64:88–98.
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb AS, DelBello M, et al. Pharmacokinetics and safety of vortioxetine in pediatric patients. J. Child Adolesc. Psychopharmacol. 2017;27(6):526–534.
   Web of Science ®Google Scholar
• Stein MB, Sareen J. Clinical practice. generalized anxiety disorder. N. Engl. J. Med. 2015;373:2059–2068.
   PubMed Web of Science ®Google Scholar
• Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin. Pharmacother. 2015;16:1669–1681.
   PubMed Web of Science ®Google Scholar
• Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin. Pharmacother. 2018;883–894.
   PubMed Web of Science ®Google Scholar
• Goddarda W, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry. 2001;58(7):681–686.
   Google Scholar
• Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J. Clin. Psychiatry. 2004;65:244–248.
   PubMed Web of Science ®Google Scholar
• Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J. Am. Acad. Child Adolesc. Psychiatry. 1992;31:29–33.
   PubMed Web of Science ®Google Scholar
• Graae F, Milner J, Rizzotto L, et al. Clonazepam in childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry. 1994;33:372–376.
   PubMed Web of Science ®Google Scholar
• Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch. Gen. Psychiatry. 2008;65:551–562.
   PubMed Web of Science ®Google Scholar
• Nelson JC. Tricyclic and tetracyclic drugs. essentials clin. psychopharmacol. 3rd ed; 2013. p. 5–28.
   Google Scholar
• Feighner JP. Mechanism of action of antidepressant medications. J. Clin. Psychiatry. 1999;60(Suppl 4):4–11.
   PubMed Web of Science ®Google Scholar
• Bailey B, Buckley NA, Amre DK. A meta-analysis of prognostic indicators to predict seizures, arrhythmias or death after tricyclic antidepressant overdose. J. Toxicol. - Clin. Toxicol. 2004;42(6):877–888.
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry. 1993;50:884–895.
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J. Clin. Psychiatry. 1988;49:293–301.
   PubMed Web of Science ®Google Scholar
• Rynn M, Garc??a-Espa??a F, Greenblatt DJ, et al. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. J Clin Psychopharmacol. 2003;23:505–508.
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006;7:295–309.
   PubMed Web of Science ®Google Scholar
• Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J. Clin. Psychiatry. 2012;73(Suppl 1):10–16.
   PubMedGoogle Scholar
• Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. 2006;CD006115.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Mills JA, Cornwall GJ, et al. Buspirone in children and adolescents with anxiety: a review and Bayesian analysis of abandoned randomized controlled trials. J. Child Adolesc. Psychopharmacol. 2018;28(1):2–9.
   PubMed Web of Science ®Google Scholar
• Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst. Rev. 2010.
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229–236.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Geracioti TD. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr. Dis. Treat. 2007;3:237–243.
   PubMedGoogle Scholar
• Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am. J. Psychiatry. 2003;160:533–540.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50–55.
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005;183:133–143.
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240–249.
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry. 2005;62:1022–1030.
   PubMed Web of Science ®Google Scholar
• Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry. 2008;389–394.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Álvarez E, Carrasco JL, et al. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. Int. Clin. Psychopharmacol. 2015;30:265–271.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry. 2006;67:771–782.
   PubMed Web of Science ®Google Scholar
• Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur. Neuropsychopharmacol. 2017;27(12):1185–1215.
   PubMed Web of Science ®Google Scholar
• Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can. J. Psychiatry. 2011;56(9):558–566.
   Web of Science ®Google Scholar
• Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin. Pharmacother. 2006;7:1977–1987.
   PubMed Web of Science ®Google Scholar
• Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry. 2003;64:1245–1249.
   PubMed Web of Science ®Google Scholar
• Schaller JL, Thomas J, Rawlings D. Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed. 2004;6:8.
   PubMedGoogle Scholar
• Schwartz TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol. Bull. 2002;36:53–57.
   PubMedGoogle Scholar
• Pollack MH, Tiller J, Xie F, et al. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008;28:308–316.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.
   PubMed Web of Science ®Google Scholar
• Kassahun K, Mattiuz E, Nyhart E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 1997;25:81–93.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther. 1996;276:658–666.
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol. Psychiatry. 2006;59:211–215.
   PubMed Web of Science ®Google Scholar
• Guy W, Clinical Global CGI. Impressions. ECDEU Assess. Man. 1976;217–222.
   Google Scholar
• Snydermae SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder [2]. J. Clin. Psychopharmacol. 2005;497–499.
   PubMed Web of Science ®Google Scholar
• Goff DC. Risperidone and paliperidone. American Psychiatric Publishing Textbook of Psychopharmacol. 4th ed. Washington, DC; 2009. p. 627–640.
   Google Scholar
• Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J. Clin. Psychiatry. 2006;67:381–385.
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321–1325.
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Aripiprazole. Am Psychiatr Publishing Textbook. 2004;487–494.
   Google Scholar
• Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J. Clin. Psychopharmacol. 2007;27(2):207–210.
   PubMed Web of Science ®Google Scholar
• Hoge EA, Worthington III JJ, Kaufman RE, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13(6):522–527.
   Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry. 2000;57(6):553–559.
   Google Scholar
• Kreys T-JM, Phan SV. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy. 2015;35:175–188.
   PubMed Web of Science ®Google Scholar
• Mezhebovsky I, Mägi K, She F, et al. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int. J. Geriatr. Psychiatry. 2013;28:615–625.
   PubMed Web of Science ®Google Scholar
• Merideth C, Cutler AJ, She F, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int. Clin. Psychopharmacol. 2012;27:40–54.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress. Anxiety. 2010;27:964–976.
   PubMed Web of Science ®Google Scholar
• Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin. Investig. Drugs. 2009;18:1533–1540.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas AA, De Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2008;28:561–566.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Márquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J. Clin. Psychiatry. 2014;75:362–368.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Jarema M, et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. 2017;27:526–537.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J. Clin. Psychiatry. 2012;73:1002–1008.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Compton SN, Robertson B, et al. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J. Child Adolesc. Psychopharmacol. 2017;27(1):29–37.
   PubMed Web of Science ®Google Scholar
• Soeter M, Kindt M. An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol. Psychiatry. 2015;78:880–886.
   PubMed Web of Science ®Google Scholar
• Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine. 2010;17:94–99.
   PubMed Web of Science ®Google Scholar
• Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. Int. J. Neuropsychopharmacol. 2014;17:859–869.
   PubMed Web of Science ®Google Scholar
• Möller HJ, Volz HP, Dienel A, et al. Efficacy of silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur. Arch. Psychiatry Clin. Neurosci. 2018. In press.
   Google Scholar
• Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N. Engl. J. Med. 2007;356:479–485.
   PubMed Web of Science ®Google Scholar
• Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst. Rev. 2003;(1):CD003383.
   Google Scholar
• Connor KM, Davidson JRT. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int. Clin. Psychopharmacol. 2002;17:185–188.
   PubMed Web of Science ®Google Scholar
• Ernst E. A re-evaluation of kava (Piper methysticum). Br. J. Clin. Pharmacol. 2007;415–417.
   PubMed Web of Science ®Google Scholar
• Davidson J, Zhang W, Connor K, et al. Review: a psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). J. Psychopharmacol. 2010;24:3–26.
   PubMed Web of Science ®Google Scholar
• Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am. J. Psychiatry. 2005;162:1179–1187.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Mills JA, Sauley BA, et al. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry. 2018;57:235–244.
   PubMed Web of Science ®Google Scholar
• Wang Z, Whiteside SPH, Sim L, et al. Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis. JAMA Pediatr. 2017;171:1049.
   Web of Science ®Google Scholar
• Strawn JR, Welge JA, Wehry AM, et al. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress. Anxiety. 2015;32:149–157.
   PubMed Web of Science ®Google Scholar
• Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am. J. Psychiatry. 2009;166:418–426.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Zhou X, Del GC, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016;388(10047):881–890.
   Web of Science ®Google Scholar
• Murrin LC, Sanders JD, Bylund DB. Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: implications for differential drug effects on juveniles and adults. Biochem. Pharmacol. 2007;73:1225–1236.
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety. 2000;12(Suppl 1):2–19.
   PubMed Web of Science ®Google Scholar